Sign in
Not yet taking people in United StatesPhase 1/2

FGF-1 injections for leg artery disease with pain when walking

Tests FGF-1 injected into muscle in people with peripheral arterial disease.

Key facts

Who runs it
Venturis Therapeutics, Inc.
Where
Chicago, United StatesSee the site
Trial code
Registry title
FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
24 people, planned
Starts
15 Oct 2028
Expected to end
15 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • FGF-1
  • Placebo
Record updated
19 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with peripheral arterial disease who get leg pain when walking (intermittent claudication). It tests the safety of FGF-1 injections into the muscle.

Age
50 to 75 years. People over 75 and up to 80 years may be considered if they show no decline in thinking or muscle function and can fully follow the protocol.
Sex
All sexes can join.
Disease stage
Leg pain when walking for at least 6 months, stable for the past 3 months. Resting ABI ≥0.40 and <0.90 in at least one leg. Narrowing of >70% up to full blockage in the popliteal artery and/or tibial peroneal trunk, or in at least 2 tibial arteries above the ankle. Treadmill peak walking time >1 minute and < 12 minutes, limited by calf pain. Life expectancy > 1 year.
Earlier treatment
Usual medicines must be stable for 6 weeks before dosing. No leg surgery or revascularization in the past 6 months, and no peripheral angioplasty in the past 3 months. No other trial drug or device in the past 6 months. No radiation therapy and no antiproliferative drugs (e.g. thalidomide, hydroxyurea).

Main reasons for not taking part

  • Severe lack of blood flow in the leg, with pain at rest or ulcers, or any leg or toe amputation.
  • Heart attack, unstable angina, stroke or ischemic attack in the past 6 months, or NYHA class II, III or IV heart failure.
  • Any cancer now or in the past, except past basal cell skin cancer not on either leg.
  • Type I diabetes, HgbA1c >8% (64 mmol/mol), or uncontrolled high or low blood pressure.
  • Pregnant, planning pregnancy or nursing, or premenopausal women not sterilized and not using birth control.

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • Subjects considered eligible to enter the study must sign an informed consent form prior to the initiation of any study procedures. In the event that the subject must be withdrawn and is re-screened for study participation at a later date, a new informed consent form must be signed. Subjects must be competent to give written informed consent
  • Age must be ≥50 and ≤75 years of age with a life expectancy of > 1 year and leg survival > 6 months. Patients >75 and ≤80 years of age will be considered if they show no signs of cognitive or muscle function decline and are fully able to comply with the protocol
  • Patients must have experienced intermittent claudication for at least 6 months and have been stable for the past 3 months
  • Patients must have peripheral arterial disease, as confirmed by a resting ABI ≥0.40 and <0.90 based on at least one leg as measured using both the dorsal pedis and posterior tibial arteries
  • Stenosis of >70% up to total occlusion must be present in the popliteal artery and/or in the tibial peroneal trunk or at least 2 tibial arteries above the ankle without inflow limitation of the popliteal artery. Adequate popliteal inflow is defined as continuous flow from the abdominal aorta, iliac, common femoral and superficial femoral with any stenosis < 50% as determined either by intra-arterial DSA, CTA or Gd CE-MRA
  • The screening Gardner treadmill test peak walking times (PWT) must be >1 minute and < 12 minutes and limited by pain in one or both calves
  • Preexisting medication regime must be stable for 6 weeks preceding dosing

Who cannot take part

  • Leg surgery or revascularization within past 6 months or peripheral angioplasty within past 3 months or anticipated during study
  • Participation in any investigational device or drug trial within the past 6 months
  • Major surgery with the past 6 months
  • Antiproliferative drugs (e.g. thalidomide, hydroxyurea)
  • Radiation therapy
  • Treadmill walking limited by conditions other than intermittent claudication including arthritis, angina and dyspnea
  • Evidence of limb ischemia from immunologic or inflammatory disorders
  • Myocardial infarction, unstable angina, stroke or ischemic attack within past 6 months
  • New York Heart Association (NYHA) class II, III or IV heart failure, restrictive or hypertrophic cardiomyopathy or severe valvular disease
  • Hemorrhage or thrombotic events (e.g. deep vein thrombosis) within past 6 months
  • Thrombocytopenia (<100,000/µl), history of heparin-induced thrombocytopenia
  • Present of any type of cancer or history of cancer except past (but not present) basal cell dermal carcinoma not on either leg
  • Inflammatory or progressive fibrotic or myelofibrotic disorders
  • Patients experiencing bacterial or viral infection (e.g. hepatitis or HIV) or who may otherwise be febrile
  • Type I diabetes
  • Uncontrolled hypertension (≥160 systolic or ≥100 diastolic pressure) or hypotension (<90 systolic or <60 diastolic pressure)
  • Disease or drug (e.g. systemic corticosteroid) immuno-compromised
  • QTc elongation greater than 450 ms in males or 460 ms in females
  • PT (INR), PTT, urinalysis, thyroid function (T3, T4, TSH) outside normal limits
  • Hemoglobin A1c(HgbA1c) of >8%
  • Hepatic dysfunction as defined either by AST or ALT > 2.0 times the upper limit of normal
  • Serum creatinine of ≥ 2.5 mg/dl
  • Proteinuria (urine protein/creatinine ratio > 3)
  • Evidence of critical leg ischemia, i.e. ischemic rest pain or ischemic ulceration
  • Lower limb amputation of, or in, either leg including toes
  • Positive proliferative retinopathy exam
  • Total fasting cholesterol >200
  • Implanted devices not compatible with strong magnetic fields
  • Life expectance of less than 1 year
  • Females who are premenopausal and not sterilized or using adequate birth control or are either pregnant, intend to become pregnant or are nursing

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 75 years old?

Where in United States

  • Venturis TherapeuticsChicago, United StatesContact: Laurence R Meyerson, PhDNot yet recruiting

About the trial

What the trial wants to find out

FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    The dosing groups correspond to total doses of 0 µg/kg of FGF-1.

  • Human FGF-1Existing treatment, for comparison

    The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.

    Treatment: FGF-1

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication
Plain-language title
FGF-1 injections for leg artery disease with pain when walkingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT00424866, who can take part
Record updated
19 August 2026